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Minimal residual disease (MRD) in bone marrow is a pow-
erful predictor of clinical outcome in childhood acute lym-
phoblastic leukemia (ALL).1-4 MRD evaluation is included in
most treatment regimens for newly diagnosed ALL in which
it yields an important risk group stratification parameter.5-9
Multiple studies evaluating MRD continue to demonstrate
the prognostic value in newly diagnosed pediatric ALL
patients,10-12 and there is increasing evidence that MRD is also
of prognostic importance in relapsed ALL.13-18 Initial reports on
a relatively small numbers of relapsed patients13-15 have been
confirmed in a representative number of relapsed intermedi-
ate-risk ALL patients in the ALL-REZ P95/96 trial.19 Eckert et
al.19 reported that MRD after the second induction course was
the only parameter independently predicting the occurrence
of subsequent relapse. The subsequent ALL-REZ BFM 2002
trial successfully integrated MRD status into the decision to
allocate MRD good responders to chemotherapy and poor
responders to hematopoietic stem cell transplantation.16
In the study by Eckert et al.19 as well as in the majority of
previous studies on front-line protocols from the ALL-BFM
study group,1,7,20-22 MRD was assessed using a method based
on amplification of clonal antigen-receptor gene rearrange-
ments by polymerase chain reaction (PCR), which has
become the reference method in the ALL-BFM protocols.7,22
The flow cytometric (FCM) analysis of bone marrow follow-
up samples is an alternative approach to detect MRD.23-26 Due
to certain advantages/benefits of FCM-MRD monitoring
(monitoring of higher numbers of patients, a faster turn-
around time, less time- and labor-intensive, less expensive)
this method has become increasingly important as a comple-
mentary technique to PCR or even a preferred approach in
ALL protocols.27 Detection of blasts by FCM is based on anti-
gen expression differences between normal and malignant B-
lineage cells. While normal mature B lymphocytes and B-cell
progenitors (hematogones) reveal an ordered pattern of anti-
gen expression on the cell surface, malignant cells may be
identified by their leukemia-associated immunophenotypes,
which are usually defined at diagnosis.24,25,27 During therapy,
however, the regeneration pattern of normal hematogones28
and the initial leukemia-associated immunophenotypes of
leukemic cells29-33 may be considerably distorted. The major
challenge of FCM-MRD analysis is, therefore, to distinguish
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Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method for evaluating
minimal residual disease in treatment protocols for primary acute lymphoblastic leukemia. Given considerable dif-
ferences between primary and relapsed acute lymphoblastic leukemia treatment regimens, flow cytometric assess-
ment of minimal residual disease in relapsed leukemia requires an independent comprehensive investigation. In
the present study we addressed evaluation of minimal residual disease by flow cytometry in the clinical trial for
childhood relapsed acute lymphoblastic leukemia using eight-color flow cytometry. The major challenge of the
study was to reliably identify low amounts of residual leukemic cells against the complex background of regener-
ation, characteristic of follow-up samples during relapse treatment. In a prospective study of 263 follow-up bone
marrow samples from 122 patients with B-cell precursor acute lymphoblastic leukemia, we tested various B-cell
markers, adapted the antibody panel to the treatment protocol, and evaluated its performance by a blinded parallel
comparison with the polymerase chain reaction data. The resulting eight-color single-tube panel showed a consis-
tently high overall concordance (P<0.001) and, under optimal conditions, sensitivity similar to that of the reference
polymerase chain reaction method. Overall, evaluation of minimal residual disease by flow cytometry can be suc-
cessfully integrated into the clinical management of relapsed childhood acute lymphoblastic leukemia either as
complementary to the polymerase chain reaction or as an independent risk stratification tool. ALL-REZ BFM 2002
clinical trial information: NCT00114348
Minimal residual disease analysis by eight-color flow cytometry 
in relapsed childhood acute lymphoblastic leukemia
Leonid Karawajew,1 Michael Dworzak,2 Richard Ratei,3 Peter Rhein,1 Giuseppe Gaipa,4 Barbara Buldini,5 Giuseppe
Basso,5 Ondrej Hrusak,6 Wolf-Dieter Ludwig,3 Günter Henze,1 Karl Seeger,1 Arend von Stackelberg,1 Ester Mejstrikova,6
and Cornelia Eckert1
1Department of Pediatric Oncology/Hematology, Charité Universitätsmedizin, Berlin, Germany; 2St. Anna Children's Hospital and
Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, Austria; 3Robert-Roessle-Clinic in the
HELIOS Klinikum Berlin, Germany; 4Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca, Ospedale
San Gerardo, Monza, Italy; 5Laboratory of Pediatric Onco-Hematology, Department of Pediatrics, University Hospital of Padova, Italy;
6Department of Pediatric Hematology and Oncology, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague,
Czech Republic 
ABSTRACT
leukemic cells from normal B-lineage subpopulations in
bone marrow during treatment. While this can be more
easily accomplished during times of continued chemother-
apy and cytopenia, it is decisively more challenging in
periods of hematopoietic regeneration. The performance
of the FCM-MRD method depends, therefore, on the time
points of application within a given treatment protocol,
and the results of the FCM-MRD evaluation obtained
within one study cannot be extrapolated directly to anoth-
er trial if different treatment protocols are used.
In the front-line ALL protocols, extensive analyses of
FCM-MRD and comparisons with PCR-MRD have been
performed.12,14,25,26,34-38 However, given considerable differ-
ences between front-line and relapsed ALL treatment reg-
imens, the FCM-MRD in relapsed ALL and its relationship
to PCR-MRD requires an independent comprehensive
investigation. Moreover, FCM-MRD, being largely the
methodology of detection of rare cells, is a technically
challenging and rapidly developing field of flow cytome-
try.25,27 While the majority of FCM-MRD studies have been
performed using three- and four-color techniques, the
recent reports on MRD data within front-line AIEOP-BFM
ALL 2000 and DCOG-ALL10 protocols demonstrated
improvement of the MRD analysis using six- and seven-
color FCM.35,39
In the present study we addressed FCM-MRD in the
ALL-REZ BFM 2002 relapse trial for childhood ALL using
eight-color FCM and compared it with PCR-MRD in a
prospective blinded study. We analyzed MRD levels by
both methods in a total of 263 follow-up bone marrow
samples from 122 patients with B-cell precursor (BCP)-
ALL. During the study, we tested various antibody combi-
nations, defined the protocol-adjusted antibody panel, and
evaluated qualitative and quantitative concordance
between FCM-MRD and PCR-MRD.  
Methods
Patients and treatment
Patients in the presented study cohort had a first BCP-ALL
relapse and were enrolled in the international trial ALL-REZ BFM
2002. Patients’ samples were obtained in accordance with the
informed consent guidelines of the local medical ethics commit-
tees. The research protocol for the assessment of MRD and the
treatment protocol were approved by the local medical ethics
committees. The clinical characteristics of the study cohort are
presented in Online Supplementary Table S1. Standard-, intermedi-
ate- and high-risk groups and their treatment strategies are
defined in the Online Supplementary Material and Methods and
Online Supplementary Table S2. 
Minimal residual disease assessment by polymerase
chain reaction and flow cytometry
In order to analyze and optimize the FCM-MRD methodology,
263 follow-up bone marrow samples from 122 patients were
assessed by FCM in parallel to PCR analysis at multiple time
points during the treatment. Samples were collected and initially
prepared uniformly as described in the Online Supplementary
Material and Methods. PCR-MRD measurements were performed
as described previously.15,19,40
FCM-MRD was assessed on the basis of standard protocols
described for four-color FCM36,41 and modified in order to fit the
eight-color FCM. All tubes contained a cell-permeant nucleic acid
dye Syto41, which allowed identification of nucleated cells. MRD
was quantified as the percentage of leukemic cells within the
nucleated cell gate. Antigen expression was quantified as mean
fluorescence intensity (MFI).42,43 MFI values were corrected for
background staining using antigen-negative lymphocyte/nor-
moblast subpopulations. In the absence of appropriate negative
subpopulations (for the antigens Bcl-2, CD58, CD44), isotype- and
fluorochrome-matched irrelevant monoclonal antibodies were
used as negative controls. The eight-color FCM was performed
using a BD CANTO II flow cytometer (Becton Dickinson, San
Jose, CA, USA).
Protocol-specific optimization of flow cytometry 
assessment of minimal residual disease by antibody
testing and comparison with polymerase chain 
reaction data
In order to determine the panel of monoclonal antibodies which
would correspond to the specific features of the ALL-REZ BFM
2002 protocol, a series of measurements with differing monoclon-
al antibody combinations was performed in parallel with PCR-
MRD in a blinded manner. During this testing phase, three retro-
spective comparisons of the FCM and PCR data were carried out,
in order to get feedback on the quality of the FCM-MRD analysis.
After the testing phase, the final panel was determined and vali-
dated in a subsequent series of measurements. The antibody tubes
tested are shown in Online Supplementary Table S3. A list of anti-
bodies, antibody clones, fluorochromes, and manufacturers is pro-
vided in Online Supplementary Table S4.
Statistical analysis
In the qualitative analysis of concordance between FCM and
PCR results, a binary classification test was performed at different
MRD cut-off levels. The analysis provided statistical measures of
the performance of the FCM method in comparison to PCR as the
reference method: sensitivity (% of concordant positive cases in
relation to the total number of positive PCR-MRD cases), specifici-
ty (% of concordant negative cases in relation to the total number
of negative PCR-MRD cases) and overall concordance (% of all
concordant cases). 
In the quantitative comparison, general associations of FCM
and PCR data as continuous variables were evaluated using bivari-
ate non-parametric Spearman correlation statistics. To compare
the FCM-MRD and PCR-MRD methods more specifically, Bland-
Altman analysis44 was used.
All calculations, including box plot graphics and the basic oper-
ations for the Bland-Altman analysis (one-sample t-test and linear
regression analysis), were performed with IBM SPSS Statistics 21
software (IBM Corporation, USA). 
Results
Protocol-specific optimization of the eight-color flow
cytometry panel  
The distinctive feature of the follow-up MRD samples
was the presence of normal hematogones (Figure 1), with
a predominance of early B-cell precursors (regeneration
burst, Online Supplementary Figure S1). Hematogones were
present in the majority of bone marrow samples (73%) at
various levels (0.001% - 49%/nucleated cells, mean 1.1%).
In particular low amounts of CD10+ leukemic cells could
not be reliably identified against this complex background
of regeneration using only the basic panel consisting of
CD19, CD10, CD20, CD34, and CD45 antibodies (Figure
1), which have been proven to be indispensable in the
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front-line FCM-MRD studies.24,27,41,45 In order to optimize
the monoclonal antibody panel, we tested several cell
markers in addition to the basic combination of antibod-
ies. The following surface antigens were tested: CD58 (the
useful marker of blasts in the front-line protocol46), CD22
(the earliest B progenitor surface marker42), CD24 (B line-
age marker), CD38 (a widely expressed hematopoietic
antigen), and CD44, CD72, and CD86 (antigens with a
potential to discriminate normal and leukemic progeni-
tors, described by Coustan-Smith et al.43). In addition,
cytoplasmic expression of TdT (normal and leukemic pro-
genitors) and Bcl-2 (anti-apoptotic protein with an often
increased expression in malignant cells43,47) were tested.
The testing was performed using at least two antibody
combinations (tubes). One tube, which contained the
most established antibody combination of CD10, CD19,
CD20, CD22, CD34, CD58, and CD45 in the ALL-BFM
front-line protocol, was used in all cases. The second,
experimental tube contained variable combinations of
antibodies (Online Supplementary Table S3). Each antibody
combination was tested in a series of 10 to 50 follow-up
samples containing CD10+ leukemic and/or hematogone
subpopulations. Mean expression values are presented in
Online Supplementary Table S5 and the distributions of the
measured values within sample series are depicted in the
Figure 2. Expression of CD38, CD22, CD58, CD72 and
Bcl-2 was statistically different between hematogones and
leukemic cells (Online Supplementary Table S5). In particu-
MRD assessment by 8-color flow cytometry in relapsed ALL
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Figure 1. FCM analysis of MRD samples using the protocol-adjusted CD38-tube. All dot plots are pre-gated for Syto41- and CD19-positivities.
(A-C) BCP-ALL samples with different levels of B-cell regeneration (green dots) and MRD (red dots). (D) T-ALL sample with a high level of B-cell
regeneration (green dots) as cross-lineage negative control staining.
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lar, there was a 6-fold difference of expression of CD38.
Importantly, there was a strikingly low variability of
CD38 expression in hematogones (Figure 2), which has
been characteristic of all CD10-positive stages of B-cell
regeneration. In the hematogone fraction, the "noise"
background of the CD38 signal was extremely low and
free from randomly stained cells (dot plots CD10 versus
CD38 in Figure 1D). CD38 expression in leukemic cells
(total MFI range: 647-1.1) was below the lowest value in
hematogones (total MFI range: 1030-231) in the majority
of samples (46 of 50, MFI range: 229-1.1). This analysis
indicates that CD38 is the most promising marker for dis-
criminating normal and leukemic CD10+ B-cell progenitors
in a single antibody tube setting. For the other antigens
with statistically significant differences, the absolute fold
difference varied between 1.5 and 2.9 (Online
Supplementary Table S5) with largely overlapping distribu-
tions in normal and leukemic precursors (Figure 2). The
usefulness of these markers, in particular Bcl-2 and CD72,
in selected cases could not be excluded; however, a more
detailed investigation would require a considerably higher
number of cases, which would be difficult to achieve
given that relapsed BCP-ALL is a rare disease. 
For the CD10-/low BCP-ALL cases, which are considerably
less frequent (27/263, 10.2%, in our MRD series), the dis-
crimination of leukemic cells and CD19+CD10- plasma
cells is most important. Plasma cells demonstrated consis-
tently high levels of CD38 expression (mean=1600 MFI;
range, MFI 2511-906; n=20), significantly exceeding those
of hematogones and leukemic cells (Online Supplementary
Table S5 and Figure 2). Together with the negativity of
plasma cells for expression of CD22 and CD34 (data not
shown), the CD38-tube panel was able to effectively dis-
criminate CD10-/low BCP-ALL and plasma cells. 
The CD22 antibody was included as the B-lineage com-
mitment marker expressed at all stages of B-cell regenera-
tion, in particular at the stage preceding CD19 expres-
sion.42 These very early CD19-CD34+CD22+ B-cell progen-
itors had a CD10+TdT+ immunophenotype (Online
Supplementary Figure S2), and their presence in bone mar-
row correlated with the percentage of normal CD19+
hematogones (Online Supplementary Figure S3). Already
small amounts of these cells were indicative of the initial
process of CD19+ B-cell regeneration (Online Supplementary
Figure S3).  
With regard to the basic combination of CD10, CD19,
CD20, CD34 and CD45 antibodies, we did not observe
significant changes in expression during therapy, in con-
trast to what was reported with the front-line ALL-BFM
protocol.29-33 In particular, the aberrantly high expression of
CD10 and CD34, if present at diagnosis, was helpful in
detecting MRD (Figure 1C and data not shown). 
As the final result we established an eight-color single-
tube panel containing CD10, CD19, CD20, CD22, CD34,
CD38, and CD45 antibodies and a Syto41 cell-permeant
nucleic acid dye. This panel is subsequently referred to as
the "CD38-tube". The preceding measurements will be
considered together and referred to as the "CD58-tube". 
CD38- and CD58-tube minimal residual disease series
The testing phase was performed using 159 samples and
the CD38-tube was validated using 104 samples. The
nucleated cell counts were >105 in the majority of cases
(96%), and in 67% of cases the nucleated cell count was
>3x105. In 11 cases (4%) the number of nucleated cells was
below 105; nonetheless, we did not exclude these cases
from the subsequent comparison with PCR, in order to
keep the analysis close to routine conditions. Values of 106
and more were present in 21 cases (8%).
With regard to the most frequent aberrations, which
were particularly instructive to distinguish leukemic and
normal precursors, the expression of CD38 was lower on
blasts than on hematogones in 67% of ALL cases. An aber-
rantly high expression of CD10 and CD34 was present in
38% and 17% of cases, respectively. Together, these aber-
rations were helpful in FCM-MRD assessement in 96% of
cases. In the remaining cases an aberrantly low CD45
expression was helpful. We investigated the combination
of CD58 and CD38 in a series of MRD samples (n=30) in
parallel to the CD38-tube validation series; however this
combination did not reveal any synergy in the identifica-
tion of leukemic cells (data not shown).
In order to investigate potential detection limits of FCM-
MRD in terms of absolute MRD cell counts, we set the cri-
terion for quantifiable MRD positivity at the level of 10
cells or more. As an additional tool, for the cases with <10
blast cells, we introduced the term of "positive but not
quantifiable" (pbnq) MRD in analogy to PCR. The distri-
bution of MRD levels within the tested series is shown in
Figure 3. There were considerably fewer MRD-negative
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Figure 2. Box plot presenta-
tion of marker expression in
hematogones (white) and
BCP-ALL cells (grey). The
markers are ordered in
descending order of mean
expression values in hemato-










samples (35.6% versus 52.8%) and more positive samples
at pbnq levels (14.4% versus 3.1%) using the CD38-tube in
comparison with the CD58-tube (Figure 3). In order to
exclude cohort-specific variability, we estimated the con-
tributions of CD58 and CD38 in a retrospective analysis
by omitting these antibodies in the interpretation of MRD
data ("leave-one-out" analysis) (Figure 3). This analysis
demonstrated that there were no cases in which CD58
contributed decisively to the identification of leukemic
cells. In contrast, CD38 was indispensable in 15 out of 67
positive cases. The “leave CD38 out” MRD histogram
shifted toward negative cases and, in particular at low
MRD levels, the frequency of positive cases decreased
(Figure 3). 
Concordance analysis of flow cytometry and
polymerase chain reaction minimal residual 
disease assessment
Using the PCR data as the reference, we first investigat-
ed the performance of FCM-MRD near to the detection
limit of 10 cells (Online Supplementary Table S6). FCM-
MRD was highly concordant with PCR-MRD down to the
detection limit of 10 cells, while at the pbnq level the num-
ber of discordant cases increased significantly. This analy-
sis, therefore, indicated the eligibility of the 10-cell detec-
tion limit. 
Qualitative concordance between FCM and PCR data
was analyzed at different MRD cut-off levels in terms of
sensitivity, specificity and overall concordance of FCM in
relation to PCR as the reference method (Table 1). At the
0.1% cut-off (the hematopoietic stem cell transplanta-
tion-relevant MRD level in the ALL-REZ BFM 2002 trial,
Online Supplementary Materials and Methods), the FCM-
MRD sensitivity was 74%, independently of the anti-
body panel (Table 1). At the 0.01% cut-off, which has
been the usual criterion of MRD-positivity in the majority
of reports,12,35-38,41 the sensitivity increased, particularly for
the CD38-tube (88% versus 80% for the CD58-tube). The
difference in sensitivities between the antibody panels
became consequently higher when samples were classi-
fied as MRD positive or negative with no percentage cut-
off (90.8% versus 69.7% for the CD38- and CD58-tubes,
respectively). 
There was a considerable variance in the ratio of discor-
dant FCM-PCR+ and FCM+PCR- samples between the
CD58- and CD38-tube series when no cut-off was
applied. In the CD58-tube series, the number of false neg-
ative (n=30) and false positive (n=6) cases was markedly
shifted toward FCM-/PCR+, in accordance with the lower
relative sensitivity of the FCM-MRD method reported
previously.35-38,41 In contrast, for the CD38-tube the number
of FCM-PCR+ and FCM+PCR- cases was approximately
equal (n=6 and n=8, respectively, Table 1).
The quantitative comparison of FCM and MRD is
shown in Figure 4. The bivariate correlation of FCM and
PCR was highly significant (P<0.001). The correlation
coefficients were higher for the CD38-tube series than for
the CD58-tube one (0.92 and 0.82, respectively). Similarly
to the analysis of qualitative concordance at positive/neg-
ative MRD level (Table 1), the CD38-tube but not the
CD58-tube series revealed similar numbers of
FCMpbnq/PCR-, FCMpbnq/PCRpbnq and FCM-/PCRpbnq cases
(Figure 4). 
With regard to the specificity (Table 1), this parameter
decreased in the CD38-tube series when no cut-off was
applied, due to the increased number of the discordant
PCR-FCM+ cases at a pbnq level.  Although seemingly in
contradiction with the improved performance of the
CD38-tube panel, the decrease of specificity is in accor-
MRD assessment by 8-color flow cytometry in relapsed ALL
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Figure 3. Histograms displaying the distribution of different MRD lev-
els within testing series. The height of the bar (y-axis) corresponds to
the relative frequency of the samples falling within the indicated
MRD interval (x-axis). The series using experimental CD58-tubes
comprised 159 samples, the series using the CD38-tube comprised
104 samples.
Table 1. Qualitative concordance of FCM-MRD in relation to PCR-MRD at different MRD cut-off levels and with no percentage cut-off.
FCM + - + - Sensitivity Specificity Concordance
PCR + + - - % % %
Cut-off: 0.1%
"CD58-tube" 41 14 3 102 74.5 97.1 89.4
"CD38-tube" 23 8 0 72 74.2 100 92.2
Cut-off: 0.01%
"CD58-tube" 56 14 5 85 80.0 94.4 88.1
"CD38-tube" 37 5 3 58 88.1 95.1 91.3
Positive / negative
"CD58-tube" 69 30 6 54 69.7 90.0 77.4









































dance with similar detection limits of the FCM and PCR
methods. In fact, as MRD levels in the samples approach
the detection limit, the probability increases that the sam-
ple measured by one method will be a true-negative and
by the other method a true-positive. In the Online
Supplementary Discussion we consider this aspect in more
detail.
Analysis of quantitative differences between flow
cytometry and polymerase chain reaction minimal
residual disease assessment
In spite of the high bivariate correlation, the majority of
the points lay either on or below the 1:1 identity line, indi-
cating lower FCM versus PCR values (Figure 4). This obser-
vation was statistically confirmed by Bland-Altman analy-
sis, the algorithm used to compare two different methods
of measurement.44 After logarithmic transformation
(applicable to the double positive quantifiable cases,
n=104), the estimated differences of PCR and FCM values
(LDIFF) were significantly different from zero in a one-
sample t-test. The mean LDIFF was 0.41±0.05 (95% con-
fidence interval 0.32–0.51), equivalent to a linear factor of
2.5 (Figure 5). The linear regression analysis demonstrated
that LDIFF was not significantly dependent on the mean
of logarithmic values of PCR-MRD and FCM-MRD
(LMEAN), i.e. FCM-MRD and PCR-MRD differed over
the whole range of MRD levels (Figure 5). 
Since the background of hematogones may potentially
interfere with FCM-MRD and PCR-MRD analyses, we
performed Bland-Altman analysis for cohorts with differ-
ent levels of the MRD and regeneration. If the cohorts
were limited to the cases with a reliable number of detect-
ed blasts (MRD cells >100) and low regeneration (hemato-
gones <100), the mean value of LDIFF did not change sig-
nificantly (0.37±0.07, P<0.001, n=45). In the total absence
of regeneration (<10 hematogones), the difference again
did not change significantly (0.35±0.08, P<0.001, n=36). In
accordance, there was no significant correlation of either
PCR-MRD or FCM-MRD with hematogone levels in lin-
ear regression analysis (data not shown).
Furthermore, in order to check the impact of the sample
quality reflected by nucleated cell percentage, we investi-
gated the relation between LDIFF and nucleated cell values
by linear regression analysis. There was no significant cor-
relation between these parameters (data not shown).
One of the methodological differences between the two
methods is that the FCM signal in follow-up samples does
not depend quantitatively on the initial signal level, while
PCR-MRD values are linked to the initial PCR signal in the
diagnostic sample (quantitative presence of a major or
small subclone). A potential error at diagnosis may, there-
fore, result in a consistent deviation from the true MRD
value, which could be potentially detected in the follow-
up series for the same patient (intrapatient MRD series). In
the total cohort of 122 patients, there were 38 patients
with three or more follow-up measurements. In 15 out of
these 38 patients, the intrapatient MRD series consisted of
at least three positive time points, thus allowing statistical
analysis by one-sample t-test and the estimation of the
mean LDIFF values. As a result, the series could be classi-
fied into three groups with different mean LDIFF values:
highly concordant (LDIFF=0.0±0.1, n=4), highly discor-
dant (≥1.0, n=3) and intermediate (0.20-0.85, n=8). The
PCR versus FCM data for the highly concordant and highly
discordant groups are listed in Table 2. The FCM re-analy-
sis of diagnostic and MRD samples from discordant series
did not reveal immunophenotypic heterogeneity of the
leukemic cell population or misinterpretation of the data.
We also re-analyzed PCR performance in the intrapatient
MRD series with highly discordant and concordant FCM-
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Figure 4. Quantitative comparison of MRD estimates by FCM and PCR using experimental CD58-tubes (A) and the protocol-adjusted CD38-






























MRD and PCR-MRD levels (Online Supplementary Table
S7). In the discordant series, samples from one patient
(#13) revealed two clones with different Ct values at diag-
nosis and different kinetics of response to treatment.
Using the smaller subclone as the major one may have
resulted in over-interpretation of quantitative results.
However, there was no evidence for the presence of sub-
clones which could explain the FCM/PCR differences in
the patients #14 and #15.  In the concordant series there
were no cases with more than one subclone (Online
Supplementary Table S7).
Flow cytometry minimal residual disease assessment 
at the time point after induction treatment
MRD after the completion of induction therapy was
used for risk stratification (indication for hematopoietic
stem cell transplantation) in the relapse trial ALL-REZ
BFM 2002.19 Of 63 cases assessed at this time point, 40
patients had PCR-MRD <10-3 and consequently were not
allocated to transplantation after consolidation treatment.
In this cohort, there was only one case which showed
MRD >10-3 by FCM. The number of cases which could,
therefore, potentially provide information on an inde-
pendent clinical impact of FCM-MRD was too low for sta-
tistical analysis. Methodologically, the low number of the
PCR-MRD <10-3 / FCM-MRD ≥10-3 cases is in accordance
with the overall shift of the LDIFF toward positive values
(Figure 5).
Discussion
In the present study, we report on MRD detection of
leukemic cells in bone marrow samples from patients with
first ALL relapse enrolled in and treated according to the
relapse trial ALL-REZ BFM using eight-color FCM and its
relation to PCR-MRD detection. During the study a proto-
col-specific adaptation of the antibody panel was per-
formed, starting with the panel established in the front-
line ALL-BFM 2000 protocol. With the latter protocol, con-
siderable changes of leukemia-associated immunopheno-
types were frequently observed in MRD cells after pred-
nisolone treatment prephase29-32 with a genome-wide shift
toward an immunophenotype of normal B cells.33 During
induction therapy in the ALL-BFM 2000 protocol hemato-
gones were usually absent in bone marrow, but appeared
at day 78 after treatment cessation and the resting phase
showing the “classical” B-cell regeneration pattern with
precursors distributed over different maturation stages in
synchronous proportions.28,42
In comparison to the front-line regimen the ALL-REZ
BFM 2002 protocol is characterized by more intensive
chemotherapy blocks. Consequently, the patients’ bone
marrow becomes aplastic and needs rest periods after
treatment for the recovery of hematopoiesis. In our study,
MRD assessment by 8-color flow cytometry in relapsed ALL
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Table 2. Intrapatient MRD series with low (A) and high (B) levels of difference between PCR-MRD and FCM-MRD (mean LDIFF).
A Patient # 1 Patient # 2 Patient # 3 Patient # 4
timepoint PCR-MRD (%) FCM-MRD (%) PCR-MRD (%) FCM-MRD (%) PCR-MRD (%) FCM-MRD (%) PCR-MRD (%) FCM-MRD (%)
1 0.11 0.11 1.0 3.9 0.49 0.53 2.0 2.0
2 0.05 0.02 1.5 1.9 0.63 0.32 0.35 0.39
3 0.008 0.009 2.3 1.2 0.12 0.11 1.8 3.0
4 n.a. n.a. 3.1 2.9 n.a. n.a. 5.7 3.7
mean LDIFF -0.1 0.0 0.1 0.0
t-test* n.s. n.s. n.s. n.s.
B Patient # 13 Patient # 14 Patient # 15
timepoint PCR-MRD (%) FCM-MRD (%) PCR-MRD (%) FCM-MRD (%) PCR-MRD (%) FCM-MRD (%)
1 0.6 0.06 6.3 0.7 60 7.2
2 1.9 0.17 31 7.0 34 2.5
3 2.2 0.25 17 0.8 1.4 0.20
mean LDIFF 1.0 1.0 1.0
t-test* P<0.05 P<0.05 P<0.05
* one-sample t-test for the difference of log(PCR-MRD) and log(FCM-MRD) / n.s = not significant.
Figure 5. Bland-Altman plot of the difference of PCR-MRD and FCM-
MRD (LDIFF) against the mean of the PCR-MRD and FCM-MRD
(LMEAN) after logarithmic transformation. The lines indicate the
estimated mean LDIFF (continuous line) and the upper and lower











hematogones were present in the majority of samples,
and the appearance of the regeneration pattern was fre-
quently asynchronous with a predominance of early
hematogone populations and absence of late ones, in
accordance with the previous study on post-chemothera-
py B lymphopoiesis.28 Of the candidate markers tested
during the FCM-MRD optimization phase, the CD38
antigen revealed  unique expression on normal hemato-
gones at multiple stages of normal regeneration. Although
CD38 has been proposed in a larger panel for MRD,25,41,48
its prominent role in the identification of normal B-cell
precursors during therapy has not yet been assessed in
detail. 
We further included CD22 antibody into the protocol-
adjusted CD38 panel. In addition to providing an inde-
pendent parameter indicative of early B-cell regeneration
(Online Supplementary Figures S2 and S3), CD22 mono-
clonal antibody may potentially substitute the CD19 anti-
body as a pan-B-cell marker for monitoring the effect of
therapeutic interventions targeting the CD19 antigen (e.g.
blinatumomab).49 Moreover, given that the CD22 antigen
is a promising target of antibody-based treatment strate-
gies,49,50 which has been included in the international trial
for relapsed ALL that follows the ALL-REZ BFM 2002
(IntReALL-2010, NCT01802814, http://clinicaltrials.gov/
show/NCT01802814), the presence of CD22 in the anti-
body panel would enable permanent expression monitor-
ing of this target in MRD samples. The CD22 antibody,
therefore, provides a reasonable enhancement of the
range of application of the single CD38-tube panel. 
The minimum detectable signal level in FCM depends on
the ratio between the levels of specific and unspecific
(noise) signals. In the three- to four-color FCM-MRD stud-
ies,34-38 the clustering of a sufficient number (n=30-50) of
positive signals was required as an additional parameter to
distinguish specific and randomly stained cells. With
increasing numbers of simultaneously registered FCM
parameters, the unspecific background can be more effi-
ciently reduced since the signals from non-leukemic cells
can be gated out better. In the present study, the applica-
tion of the optimized eight-color tube allowed the criterion
for positivity to be reduced down to 10 cells. In addition,
this panel allowed the number of tubes to be reduced to a
single one. Correspondingly, the number of acquired
events could be increased, making the acquisition of 1x106
nucleated cells realistic in the routine diagnostic setting.
The minimal number of positive events (n=10) and the
number of acquired nucleated cells (n=106) would, there-
fore, result in a potential detection limit of 10-5. Given that
the measurements in PCR-MRD assessment are usually
made on 105 cells and that the minimum detectable PCR
signal level is, at best, 1 cell/well, the relative sensitivities
of both methods under optimal conditions would become
comparable at the level of 10-5. It should be noted that opti-
mal conditions imply, in addition to the sufficient number
of acquired events, the reliable immunophenotypic dis-
crimination of normal and leukemic progenitors. In this
regard, the applicability of every antibody panel is limited,
including the antibody panel used in the present study, and
additional potential antigen candidates do, therefore, war-
rant further investigation. 
Over the whole MRD range, FCM and PCR values
showed high levels of bivariate correlation as in other
studies.12,14,34-39 In absolute values, however, FCM-MRD
levels were statistically lower than PCR-MRD values by a
factor of 2.5. Of interest, Gaipa et al.35 reported a 2.9-fold
higher mean MRD level by PCR as compared to seven-
color FCM-MRD in 266 follow-up bone marrow samples
in the front-line ALL-BFM study. Overall, differences
between quantitative FCM-MRD and PCR-MRD have
been reported in the majority of publications addressing
this issue.12,14,34-39 In addition, van der Velden et al.22 report-
ed an intra-assay variability of PCR-MRD of about 3-fold,
i.e. in a similar range as the observed variance between
PCR and FCM. 
Nonetheless, the consistent quantitative shift towards
lower FCM levels remains to be explained. Several
sources of quantitative PCR-MRD discordance have been
proposed, such as variability of biological material, lower
FCM sensitivity, high regeneration background, and pres-
ence of dead cells.12,14,25,35-39 We addressed these potential
sources of discordance experimentally. Given the uniform
pretreatment and the use of sample splitting, the influ-
ence of sample variability could be largely excluded. Our
data indicate that despite improved sensitivity the quan-
titative discrepancy remains significant. Importantly, the
statistically significant LDIFF level was also independent
of the level of regeneration background and of the per-
centage of nucleated cells. In addition to these commonly
discussed aspects, our data allowed the analysis of intra-
patient follow-up series with a sufficient number of posi-
tive MRD time points. These data suggested that the
quantitative discrepancy is not an inherent feature of the
methodologies valid for all MRD samples, but there are
cases with a consistently high concordance as well as
those with a consistently high discordance of FCM versus
PCR results. The observed consistency of discordance
throughout some MRD series indicates that at least in
some cases the source of discrepancy may originate from
use of the PCR-MRD marker presenting a smaller sub-
clone at diagnosis which might result in an over-interpre-
tation of MRD. For discordant cases with no evidence of
subclones which could explain the FCM/PCR differences,
the picture might become clearer with a more compre-
hensive analysis of clonal T-cell receptor/immunoglobulin
gene rearrangements using targeted next-generation
sequencing.
In conclusion, this is the first report on the application
of eight-color FCM for MRD assessment and its relation
to PCR-MRD detection in relapsed ALL. The study per-
formed within the ALL-REZ BFM 2002 clinical trial
involved a parallel, prospective assessment and blinded
comparison of FCM-MRD and PCR-MRD in samples
acquired from a representative number of uniformly
treated patients. During the study we tested various anti-
body combinations, defined and validated the protocol-
adjusted antibody panel, and evaluated qualitative and
quantitative concordance of FCM-MRD and PCR-MRD
assessments. The resulting single-tube panel had a sensi-
tivity similar to that of PCR-MRD, although a high num-
ber of acquired cells was not reached routinely during the
study, due to the preferential application of PCR. The sep-
arate acquisition of bone marrow samples for FCM-MRD
in the IntReALL-2010 clinical trial will overcome this
shortage. Overall, our data show that FCM-MRD assess-
ment can be successfully integrated into the clinical man-
agement of relapsed childhood ALL either independently
or as a complement to PCR-MRD risk stratification. 
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